SUPN:NSD-Supernus Pharmaceuticals Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | NASDAQ Global Market

Last Closing

USD 31.68

Change

-0.47 (-1.46)%

Market Cap

USD 1.05B

Volume

0.52M

Analyst Target

USD 29.25
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

-1.52 (-0.47%)

USD 13.60B
NBIX Neurocrine Biosciences Inc

-0.64 (-0.52%)

USD 11.63B
VTRS Viatris Inc

-0.04 (-0.45%)

USD 9.73B
LNTH Lantheus Holdings Inc

+0.04 (+0.05%)

USD 7.11B
ALKS Alkermes Plc

+0.36 (+1.19%)

USD 4.74B
ALVO Alvotech

+0.30 (+2.69%)

USD 2.92B
HCM HUTCHMED DRC

+0.03 (+0.22%)

USD 2.57B
BCRX BioCryst Pharmaceuticals Inc

-0.13 (-1.19%)

USD 2.09B
KNSA Kiniksa Pharmaceuticals Ltd

+0.18 (+0.66%)

USD 1.92B
EVO Evotec SE ADR

+0.19 (+5.03%)

USD 1.68B

ETFs Containing SUPN

IBRN iShares Trust - iShares N.. 4.04 % 0.00 %

-0.21 (-0.96%)

USD 3.31M
ROSC Hartford Multifactor Smal.. 0.00 % 0.00 %

-0.04 (-0.96%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.39% 49% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.39% 49% F 38% F
Trailing 12 Months  
Capital Gain 19.23% 74% C 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.23% 74% C 75% C
Trailing 5 Years  
Capital Gain 31.34% 74% C 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.34% 74% C 54% F
Average Annual (5 Year Horizon)  
Capital Gain 9.48% 48% F 66% D+
Dividend Return 9.48% 48% F 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.52% 97% N/A 73% C
Risk Adjusted Return 44.09% 88% B+ 76% C+
Market Capitalization 1.05B 87% B+ 79% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 47.30 52% 38%
Price/Book Ratio 1.74 51% 50%
Price / Cash Flow Ratio 10.46 27% 27%
Price/Free Cash Flow Ratio 7.73 43% 42%
Management Effectiveness  
Return on Equity 7.55% 85% 71%
Return on Invested Capital 5.89% 73% 68%
Return on Assets 2.90% 72% 76%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.